{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T02:35:26Z","timestamp":1761100526975,"version":"3.30.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2001,4,1]],"date-time":"2001-04-01T00:00:00Z","timestamp":986083200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2001,4,1]]},"DOI":"10.1038\/sj.bmt.1703007","type":"journal-article","created":{"date-parts":[[2002,9,4]],"date-time":"2002-09-04T15:51:24Z","timestamp":1031154684000},"page":"821-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myeloma"],"prefix":"10.1038","volume":"27","author":[{"given":"A","family":"Shimoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"TL","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Weber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Anderlini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Claxton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"NT","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Donato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Korbling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Alexanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2001,7,26]]},"reference":[{"key":"BF1703007_CR1","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1056\/NEJM199402173300709","volume":"330","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos M . The treatment of multiple myeloma New Engl J Med 1994 330: 484\u2013489","journal-title":"New Engl J Med"},{"key":"BF1703007_CR2","first-page":"56","volume":"13","author":"RA Kyle","year":"1995","unstructured":"Kyle RA . Prognostic factors in multiple myeloma Stem Cells 1995 13: (Suppl. 2) 56\u201363","journal-title":"Stem Cells"},{"key":"BF1703007_CR3","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1056\/NEJM199607113350204","volume":"335","author":"M Attal","year":"1996","unstructured":"Attal M, Harousseau J, Stoppa A et al. A prospective randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma New Engl J Med 1996 335: 91\u201397","journal-title":"New Engl J Med"},{"key":"BF1703007_CR4","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1200\/JCO.1996.14.5.1447","volume":"14","author":"WI Bensinger","year":"1996","unstructured":"Bensinger WI, Rowley SD, Demirer T et al. High dose therapy followed by autologous hematopoietic stem cell infusion for patients with multiple myeloma J Clin Oncol 1996 14: 1447\u20131456","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR5","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1182\/blood.V85.11.3077.bloodjournal85113077","volume":"85","author":"J Harousseau","year":"1995","unstructured":"Harousseau J, Attal M, Divine M et al. Autologous stem cell transplantation after first remission induction treatment in multiple myeloma: a report of the French registry on autologous transplantation in multiple myeloma Blood 1995 85: 3077\u20133085","journal-title":"Blood"},{"key":"BF1703007_CR6","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1038\/sj.bmt.1701182","volume":"21","author":"B Barlogie","year":"1998","unstructured":"Barlogie B, Jagannath S, Naucke S et al. Long term follow-up after therapy for high risk multiple myeloma Bone Marrow Transplant 1998 21: 1101\u20131107","journal-title":"Bone Marrow Transplant"},{"key":"BF1703007_CR7","doi-asserted-by":"publisher","first-page":"2173","DOI":"10.1200\/JCO.1999.17.7.2173","volume":"17","author":"DH Vesole","year":"1999","unstructured":"Vesole DH, Crowly JJ, Catchatourian R . High-dose melphalan with autotransplantation for refractory multiple myeloma: results of a Southwest Oncology Group phase II trial J Clin Oncol 1999 17: 2173\u20132179","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR8","first-page":"714","volume":"94","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Desikar R, Munshi M et al. Durable CR in multiple myeloma in the absence of chromosome 13 deletion and with tandem, melphalan-based, high-dose therapy. The Arkansas experience with 1000 consecutive patients Blood 1999 94: (Suppl. 1) 714 (Abstr.)","journal-title":"Blood"},{"key":"BF1703007_CR9","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1182\/blood.V88.3.838.838","volume":"88","author":"DH Vesole","year":"1996","unstructured":"Vesole DH, Tricot G, Jagannath S et al. Autotransplantation in multiple myeloma: what have we learned Blood 1996 88: 838\u2013847","journal-title":"Blood"},{"key":"BF1703007_CR10","first-page":"418","volume":"90","author":"M Attal","year":"1997","unstructured":"Attal M, Harousseau JL, Stoppa AM et al. High dose therapy in multiple myeloma: an update analysis of the IFM 90 protocol Blood 1997 90: (Suppl. 1) 418 (Abstr.)","journal-title":"Blood"},{"key":"BF1703007_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1182\/blood.V93.1.55","volume":"93","author":"B Barlogie","year":"1999","unstructured":"Barlogie B, Jagannath S, Desikan KR et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood 1999 93: 55\u201365","journal-title":"Blood"},{"key":"BF1703007_CR12","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1002\/stem.5530130718","volume":"13","author":"R Alexanian","year":"1995","unstructured":"Alexanian R, Dimopoulos MA, Delasalle KB et al. Myeloablative therapy for primary resistant myeloma Stem Cells 1995 13: (Suppl. 2) 118\u2013121","journal-title":"Stem Cells"},{"key":"BF1703007_CR13","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1182\/blood.V83.2.512.512","volume":"83","author":"R Alexanian","year":"1994","unstructured":"Alexanian R, Dimopoulos M, Smith T et al. Limited value of myeloablative therapy in late multiple myeloma Blood 1994 83: 512\u2013516","journal-title":"Blood"},{"key":"BF1703007_CR14","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood.V82.8.2324.bloodjournal8282324","volume":"82","author":"MA Dimopoulos","year":"1993","unstructured":"Dimopoulos MA, Alexanian R, Przepiorka D et al. Thiotepa, busulfan and cyclophosphamide: a new preparative regimen for autologous marrow or blood stem cell transplantation in high risk multiple myeloma Blood 1993 82: 2324\u20132328","journal-title":"Blood"},{"key":"BF1703007_CR15","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1182\/blood.V84.3.950.950","volume":"84","author":"DH Vesole","year":"1994","unstructured":"Vesole DH, Barlogie B, Jagannath S et al. High dose therapy for refractory myeloma: improved prognosis with better supportive care and double transplants Blood 1994 84: 950\u2013956","journal-title":"Blood"},{"key":"BF1703007_CR16","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/sj.bmt.1700917","volume":"20","author":"R Powles","year":"1997","unstructured":"Powles R, Raje N, Millar B et al. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment Bone Marrow Transplant 1997 20: 435\u2013443","journal-title":"Bone Marrow Transplant"},{"key":"BF1703007_CR17","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V76.9.1860.1860","volume":"76","author":"S Jagannath","year":"1990","unstructured":"Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma \u2013 identification of prognostic factors Blood 1990 76: 1860\u20131866","journal-title":"Blood"},{"key":"BF1703007_CR18","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/sj.bmt.1701805","volume":"23","author":"SV Rajkumar","year":"1999","unstructured":"Rajkumar SV, Fonseca R, Lacy MQ et al. Autotologous stem cell transplantation for relapsed and primary refractory myeloma Bone Marrow Transplant 1999 23: 1267\u20131272","journal-title":"Bone Marrow Transplant"},{"key":"BF1703007_CR19","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1200\/JCO.1999.17.5.1551","volume":"17","author":"SV Rajkumar","year":"1999","unstructured":"Rajkumar SV, Fonseca R, Lacy MQ et al. Plasmablastic morphology is an independent predictor of poor survival after autologous stem-cell transplantation for multiple myeloma J Clin Oncol 1999 17: 1551\u20131557","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR20","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/blood.V60.4.851.851","volume":"60","author":"P McLaughlin","year":"1982","unstructured":"McLaughlin P, Alexanian R . Myeloma protein kinetics following chemotherapy Blood 1982 60: 851\u2013855","journal-title":"Blood"},{"key":"BF1703007_CR21","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1200\/JCO.1989.7.1.119","volume":"7","author":"M Boccadoro","year":"1989","unstructured":"Boccadoro M, Marmont F, Tribalto M et al. Early responder myeloma: kinetic studies identify a patient subgroup characterized by very poor prognosis J Clin Oncol 1989 7: 119\u2013125","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR22","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1200\/JCO.1988.6.10.1562","volume":"6","author":"SI Bearman","year":"1988","unstructured":"Bearman SI, Appelbaum FR, Buckner CD et al. Regimen related toxicities in patients undergoing bone marrow transplantation J Clin Oncol 1988 6: 1562\u20131568","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR23","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","volume":"36","author":"BG Durie","year":"1975","unstructured":"Durie BG, Salmon S . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 1975 36: 842\u2013854","journal-title":"Cancer"},{"key":"BF1703007_CR24","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1111\/j.1365-2141.1993.tb08278.x","volume":"83","author":"MA Dimopoulos","year":"1993","unstructured":"Dimopoulos MA, Delasalle KB, Champlin R et al. Cyclophosphamide and etoposide therapy with GM-CSF for VAD-resistant multiple myeloma Br J Haematol 1993 83: 240\u2013244","journal-title":"Br J Haematol"},{"key":"BF1703007_CR25","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1002\/(SICI)1096-8652(199606)52:2<77::AID-AJH2>3.0.CO;2-2","volume":"52","author":"MA Dimopoulos","year":"1996","unstructured":"Dimopoulos MA, Weber D, Kantarjian H et al. HyperCVAD for VAD-resistant multiple myeloma Am J Hematol 1996 52: 77\u201381","journal-title":"Am J Hematol"},{"key":"BF1703007_CR26","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.1997.15.2.667","volume":"15","author":"S Giralt","year":"1997","unstructured":"Giralt S, Weber D, Colome M et al. Phase I study of cyclosporine-induce graft versus host disease in patients with multiple myeloma undergoing high dose chemotherapy with autologous stem cell rescue J Clin Oncol 1997 15: 667\u2013673","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR27","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1046\/j.1365-2141.1998.00930.x","volume":"102","author":"J Blade","year":"1998","unstructured":"Blade J, Samson D, Reece D et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and hematopoietic stem cell transplantation Br J Haematol 1998 102: 1115\u20131123","journal-title":"Br J Haematol"},{"key":"BF1703007_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P . Nonparametric estimation from incomplete observation J Am Stat Assoc 1958 53: 457\u2013481","journal-title":"J Am Stat Assoc"},{"key":"BF1703007_CR29","volume-title":"CART: Tree-structured Non-parametric Data Analysis","author":"D Steinberg","year":"1995","unstructured":"Steinberg D, Colla P . CART: Tree-structured Non-parametric Data Analysis Salford Systems: San Diego, CA 1995"},{"key":"BF1703007_CR30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables J R Stat Soc 1972 34: 187\u2013220","journal-title":"J R Stat Soc"},{"key":"BF1703007_CR31","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1182\/blood.V93.1.51","volume":"93","author":"DS Siegel","year":"1999","unstructured":"Siegel DS, Desikan KR, Mehta J et al. Age is not a prognostic variable with autotransplants for multiple myeloma Blood 1999 93: 51\u201354","journal-title":"Blood"},{"key":"BF1703007_CR32","first-page":"537","volume":"16","author":"S Singhal","year":"1995","unstructured":"Singhal S, Powles R, Milan S et al. Kinetics of paraprotein clearance after autografting for multiple myeloma Bone Marrow Transplant 1995 16: 537\u2013540","journal-title":"Bone Marrow Transplant"},{"key":"BF1703007_CR33","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1016\/S0140-6736(89)91548-1","volume":"2","author":"ME Gore","year":"1989","unstructured":"Gore ME, Selby PJ, Clark PI et al. Intensive treatment of multiple myeloma and criteria for complete response Lancet 1989 2: 879\u2013882","journal-title":"Lancet"},{"key":"BF1703007_CR34","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1200\/JCO.1994.12.4.759","volume":"12","author":"D Cunningham","year":"1994","unstructured":"Cunningham D, Paz-Ares L, Milan S et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma J Clin Oncol 1994 12: 759\u2013763","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR35","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1200\/JCO.1985.3.12.1613","volume":"3","author":"T Takahashi","year":"1985","unstructured":"Takahashi T, Lim B, Jamal N et al. Colony growth and self-renewal of plasma cell precursors in multiple myeloma J Clin Oncol 1985 3: 1613\u20131623","journal-title":"J Clin Oncol"},{"key":"BF1703007_CR36","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1600-0609.1973.tb00073.x","volume":"10","author":"OP Hansen","year":"1973","unstructured":"Hansen OP, Jessen B, Videbaek A . Prognosis of myelomatosis on treatment with prednisone and cytostatics Scand J Haematol 1973 10: 282\u2013290","journal-title":"Scand J Haematol"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/1703007","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/1703007.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T11:04:47Z","timestamp":1733569487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/1703007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,4,1]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2001,4,1]]}},"alternative-id":["BF1703007"],"URL":"https:\/\/doi.org\/10.1038\/sj.bmt.1703007","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"type":"print","value":"0268-3369"},{"type":"electronic","value":"1476-5365"}],"subject":[],"published":{"date-parts":[[2001,4,1]]},"assertion":[{"value":"12 October 2000","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2001","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2001","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}